Peptide

Amycretin

Also known as

Zenagamtide (INN / public naming; same molecule) · NNC0487-0111 · NN9487 / NN 9487 (development code) · Novo amycretin · Unimolecular amylin + GLP-1 dual agonist · GLP-1 / amylin / calcitonin receptor agonist (trial framing) · Oral amycretin (SNAC tablet discussion) · Subcutaneous amycretin (once-weekly)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Dual appetite-pathway peptide	Amycretin, also called zenagamtide, is an investigational peptide combining GLP-1 and amylin actions in one molecule.
Tablet and injection	Trial tablets use the absorption helper SNAC; injections go beneath the skin. Ordinary powder and trial tablets are not equivalent products.

Notes

Amycretin, also called zenagamtide, is an investigational peptide combining GLP-1 and amylin appetite pathways. People follow its tablet and injection programmes for quieter food noise and weight loss. Public firsthand accounts include uncertainty and persistent side effects.

Two signals in one molecule. GLP-1 and amylin help signal appetite and feeling finished with a meal. Amycretin combines their receptor actions in one peptide; CagriSema combines two drugs. Their milligram amounts are not interchangeable. Novo Nordisk June 2026 — zenagamtide naming and investigational status (Official context · Accessed 2026-09-30) · Novo's new GLP1: Amycretin — dual pathway and rankings (Community discussion · Accessed 2026-09-30)

Tablet and injection are different formulations. The tablet uses SNAC to help a swallowed peptide reach circulation; subcutaneous injections bypass digestion. Community interest in a pill does not make ordinary powder equivalent to the trial tablet or make daily oral and weekly injectable amounts interchangeable. Gasiorek et al. 2025 — oral first-in-human indexed abstract (Official context · Accessed 2026-09-30)

Source context — Novo Nordisk June 2026 — zenagamtide naming and investigational status: Sponsor source; investigational programme, not an approval or current worldwide database clearance. No commercial dose inferred.

Source context — Novo's new GLP1: Amycretin — dual pathway and rankings: Opinion and cross-trial ranking, no firsthand Amycretin use. glp1guide promotes a linked guide; comments claiming pill-only identity or settled superiority are not adopted.

Source context — Gasiorek et al. 2025 — oral first-in-human indexed abstract: API abstract only. PubMed browser challenge and Europe PMC HTML failure are not full-paper access. No numerical oral terminal half-life in this abstract.

What people notice

Quieter hunger	One self-described trial participant reported less food noise, lower appetite and 23 kg lost over nine months. Their dose and trial assignment are unverified.
A slower, uncertain account	A blinded participant reported no weight change in month one, then 1–2 kg lost over two weeks and earlier fullness by week seven. They were unsure whether they had active drug or placebo.
Persistent tradeoffs	The positive nine-month account also describes constipation throughout, no energy boost and a quiet, disconnected feeling around injection day.

Notes

Less food noise, smaller appetite. One self-described Australian participant reported hunger noise disappearing, appetite dropping and 23 kg lost over nine months, alongside improved bloodwork. Their dose and trial assignment are unverified; these personal claims explain the appeal without predicting another person's outcome. Amycretin availability — Australian participant account (Personal report · Accessed 2026-09-30)

No reliable first-dose appetite clock. The nine-month account does not specify when appetite suppression began. In a separate blinded account, weight was unchanged during month one, with 1–2 kg lost in the next two weeks. Earlier fullness was noticed by the seven-week report, but active treatment was uncertain. Amycretin availability — Australian participant account (Personal report · Accessed 2026-09-30) · Any upcoming trials? — seven-week blinded participant account (Personal report · Accessed 2026-09-30)

A slower, uncertain account. The former Retatrutide-trial participant alternated between thinking they had active Amycretin and placebo. Fullness and small later scale changes coexisted with fatigue and digestive complaints. Their uncertainty is not proven drug nonresponse. Any upcoming trials? — seven-week blinded participant account (Personal report · Accessed 2026-09-30)

Digestive effects and low intake. Constipation persisted throughout the positive nine-month report. The blinded account adds fatigue, diarrhoea, slight nausea and burping, with possible other explanations. Community concerns about insufficient food/protein and lean mass matter under strong appetite suppression; weight loss is not proof of muscle preservation. Amycretin availability — Australian participant account (Personal report · Accessed 2026-09-30) · Any upcoming trials? — seven-week blinded participant account (Personal report · Accessed 2026-09-30)

Mood and energy deserve their own attention. Less food noise did not bring an energy boost in the expanded account. The recurring disconnected feeling is a separate concern, not simply successful appetite control. Amycretin availability — injection-day feelings and unchanged energy (Personal report · Accessed 2026-09-30)

One specific 1–2-day interval. The Australian participant felt quiet and disconnected on injection day and the next day, lasting 1–2 days. They distinguished it from depression. This is an adverse-feeling interval, not a diagnosis, appetite-benefit window or bodily half-life. Amycretin availability — injection-day feelings and unchanged energy (Personal report · Accessed 2026-09-30)

Source context — Amycretin availability — Australian participant account: Identity, allocation, trial match, bloodwork and dose unverified. One uncontrolled account, not a typical response or product verification.

Source context — Any upcoming trials? — seven-week blinded participant account: Participation and dose unverified; active drug versus placebo unknown. Prior retatrutide trial confounds comparison. Pen concentration/clicks cannot establish administered amount. Remembered 5/20 mg arms are unverified.

Source context — Amycretin availability — injection-day feelings and unchanged energy: Same person as the main account; not a second independent user. Injection route depth/dose unstated; disconnected feeling is not a diagnosis, plasma measurement or satiety offset.

Doses people talk about

Community amounts	The opened firsthand accounts do not establish a self-use dose. A blinded participant's remembered 5 mg and 20 mg targets do not verify what they received.
Weekly injection trial talk	20 mg versus 60 mg weekly is a comparison of obesity-trial arms circulating in discussion, not observed community regimens.
Daily tablet trial talk	Discussion repeats 6–50 mg/day diabetes-trial amounts. The oral phase 1 trial separately included 50 mg/day and two 50 mg tablets as one daily dose after titration.

Notes

No established self-use range. Opened experience accounts do not establish an Amycretin milligram dose. The blinded participant remembers possible 5 mg and 20 mg targets, but their allocation and actual amount are unknown. Pen clicks or an mg/mL label do not supply a verified dose. Any upcoming trials? — seven-week blinded participant account (Personal report · Accessed 2026-09-30)

20 versus 60 mg weekly is trial talk. Earlier community summaries question whether 60 mg weekly added enough to the 20 mg subcutaneous obesity-trial result. Investor posts repeat daily oral 6–50 mg diabetes-trial figures. These are trial amounts circulating online, not observed community regimens. Oral amycretin 36 wk phase 2 — tolerability disagreement (Community discussion · Accessed 2026-09-30)

Formulation and exposure matter. The oral phase 1 trial included 50 mg daily and two 50 mg tablets taken as one daily dose, after titration. Its accessible abstract supplies no numerical oral terminal half-life. Those trial tablets do not establish an injectable dose or a consumer cycle. Gasiorek et al. 2025 — oral first-in-human indexed abstract (Official context · Accessed 2026-09-30)

Source context — Oral amycretin 36 wk phase 2 — tolerability disagreement: Investor community with potential financial incentives. Trial retellings and opinions, not firsthand use. Unverified AE percentages and erroneous HbA1c unit conversion are not repeated.

Half-life, onset & duration

Felt onset	No reliable first-dose appetite clock is established. The blinded account noticed earlier fullness by week seven but could not confirm active treatment.
Felt duration	Appetite wear-off is unknown. One participant's disconnected feeling lasted 1–2 days around injection day; that is an unwanted-feeling interval, not a hunger timer.
Half-life	Human injection-trial measurements were 79.0–87.9 hours after single doses and 88.0–99.0 hours with repeated weekly dosing. The inspected oral abstract gives no numerical oral value.

Notes

Appetite wear-off remains unknown. The same person describes reduced appetite and persistent constipation across nine months, without a within-week hunger curve or post-stop offset. Discussed days-to-weeks residual effects are class-based reasoning, not an observed Amycretin stopping timeline. Amycretin availability — Australian participant account (Personal report · Accessed 2026-09-30)

Measured SC elimination. Table S9 reports geometric-mean terminal half-lives of 79.0–87.9 hours after single doses and 88.0–99.0 hours with repeated weekly dosing. These human SC measurements are not appetite duration or an oral estimate. Circulated 160–180-hour minipig/patent lore is animal-origin material, not human timing. Dahl et al. 2025 — original subcutaneous supplementary appendix (Official context · Accessed 2026-09-30)

Source context — Dahl et al. 2025 — original subcutaneous supplementary appendix: SC formulation only; subgroup geometric means, not each person's value. Some PDF screenshot requests timed out, so no independent image-based table acceptance claimed. Mood event does not identify or validate Reddit participant.

Cycles people discuss

Months-long treatment	Discussion follows continuous trial titration and maintenance; one participant account spans nine months. No validated on/off cycle is described.
After stopping	The former participant moved to Wegovy and then Tirzepatide, so their account cannot show Amycretin's off-drug effect. No specific restart or taper schedule is established.

Notes

Months-long courses, not a validated on/off cycle. The participant account spans nine months. Community discussion follows continuous trial treatment and titration/maintenance, rather than a demonstrated 4–8-week cycle. Formal study durations describe the observation period, not a lasting reset of appetite. Amycretin availability — Australian participant account (Personal report · Accessed 2026-09-30)

The off-drug outcome is unresolved. The former participant moved to Wegovy, then Tirzepatide, after the trial; that transition cannot reveal Amycretin's off-drug effect. Lower-dose restarts and regain expectations in earlier discussions borrow from the wider GLP-1 class; no Amycretin-specific restart or taper schedule was established. Amycretin availability — Australian participant account (Personal report · Accessed 2026-09-30)

Stacks

Other appetite drugs	The accounts mainly compare Amycretin with Semaglutide, Tirzepatide, CagriSema and Retatrutide. Extra GLP-1 or amylin drugs raise concerns because Amycretin already engages both pathways.
Supportive habits discussed	Protein-focused intake, resistance training, hydration and smaller meals appear in broader community discussion; they do not establish muscle preservation with Amycretin.

Notes

A possible next option after other appetite drugs. Discussion compares Amycretin with Semaglutide, Tirzepatide, CagriSema and Retatrutide. Some see an upgrade; others reject simple rankings. Early trial percentages at different durations and in different populations cannot decide which works best for an individual. Novo's new GLP1: Amycretin — dual pathway and rankings (Community discussion · Accessed 2026-09-30) · Amycretin early stage results — CagriSema comparison headline (Secondhand community claim · Accessed 2026-09-30)

Comparisons do not validate stacks. Community discussion generally compares Amycretin with other incretins/amylins rather than combining them. It already engages two appetite pathways; extra GLP-1 or amylin drugs add interaction uncertainty. Broader class concerns include gallbladder/pancreatitis issues and hypoglycaemia with insulin or sulfonylureas, rather than proven Amycretin-specific interaction rates.

Already dual: GLP-1 + amylin in one molecule — stacking another full GLP-1 RA, dual (tirz), triple (reta), or CagriSema is widely framed as redundant polypharmacy with extra GI risk. [community]

Body composition and supportive habits remain questions. Community discussion credits protein-focused intake, resistance training, hydration and smaller meals during strong appetite suppression. These are broader habits people discuss, not evidence that Amycretin spares muscle or a prescription for managing its side effects.

Source context — Amycretin early stage results — CagriSema comparison headline: Secondary clinical headline compares different studies and durations; does not establish superiority or a community dose.

Watch for

Digestion and low intake	Reports include persistent constipation, diarrhoea, nausea, burping and fatigue. Strong appetite suppression also raises concerns about too little food or protein.
Mood and energy	One participant describes recurring disconnection without more energy. A trial appendix separately records an anhedonia-related withdrawal; it does not identify or diagnose the online participant.
Unverified listings	A vial label cannot establish identity, purity, sterility or equivalence to the investigational trial product.

Notes

A separate mood event. The appendix records an anhedonia-related withdrawal—loss of pleasure—in one participant. This does not diagnose or validate the online account's disconnected feeling. Dahl et al. 2025 — original subcutaneous supplementary appendix (Official context · Accessed 2026-09-30)

A listing is not an identified trial product. Opened availability threads mostly contain anticipation, not completed self-use logs. A vial name does not establish identity, purity or sterility. No universal storage life follows from a research label. Amycretin? — anticipation and access uncertainty (Community discussion · Accessed 2026-09-30)

Source context — Amycretin? — anticipation and access uncertainty: Availability claims are dated hearsay; intention to enter a trial is not experience. No identity, supply or use protocol validated.

Full notes

What Amycretin is

Two signals in one molecule. GLP-1 and amylin help signal appetite and feeling finished with a meal. Amycretin combines their receptor actions in one peptide; CagriSema combines two drugs. Their milligram amounts are not interchangeable. Official context Reddit · r/glp1peptides
Tablet and injection are different formulations. The tablet uses SNAC to help a swallowed peptide reach circulation; subcutaneous injections bypass digestion. Community interest in a pill does not make ordinary powder equivalent to the trial tablet or make daily oral and weekly injectable amounts interchangeable. Official context Community

What people hope to get

Less food noise, smaller appetite. One self-described Australian participant reported hunger noise disappearing, appetite dropping and 23 kg lost over nine months, alongside improved bloodwork. Their dose and trial assignment are unverified; these personal claims explain the appeal without predicting another person's outcome. Personal report
A possible next option after other appetite drugs. Discussion compares Amycretin with Semaglutide, Tirzepatide, CagriSema and Retatrutide. Some see an upgrade; others reject simple rankings. Early trial percentages at different durations and in different populations cannot decide which works best for an individual. Reddit · r/glp1peptides Reddit · r/CagriSema

Doses people discuss

No established self-use range. Opened experience accounts do not establish an Amycretin milligram dose. The blinded participant remembers possible 5 mg and 20 mg targets, but their allocation and actual amount are unknown. Pen clicks or an mg/mL label do not supply a verified dose. Personal report
20 versus 60 mg weekly is trial talk. Earlier community summaries question whether 60 mg weekly added enough to the 20 mg subcutaneous obesity-trial result. Investor posts repeat daily oral 6–50 mg diabetes-trial figures. These are trial amounts circulating online, not observed community regimens. Community Reddit · r/NovoNordisk_Stock
Forms and units matter. Community discussions contrast weekly convenience with daily tablet logistics and warn about mg/mcg confusion: 0.3 mg equals 300 mcg. Semaglutide starting doses and CagriSema component ratios do not transfer to Amycretin. Community

Half-life: circulated claims and their origins

About four days versus seven days. Doserly's commercial guide cites roughly 3.5–4 days from human research. WikiPep estimates about seven days from weekly dosing. Neither is a user measurement, and a weekly schedule does not prove seven-day elimination. The inspected primary SC values are separate supporting context below. Community guide Community guide
Half-life is not a hunger timer. It describes falling drug concentration, not when somebody feels hungry again. Discussion anticipates multi-day exposure and accumulation with repeated use; that does not measure an individual's appetite duration or establish oral and injectable equivalence. Community

When people first notice something

No reliable first-dose appetite clock. The nine-month account does not specify when appetite suppression began. In a separate blinded account, weight was unchanged during month one, with 1–2 kg lost in the next two weeks. Earlier fullness was noticed by the seven-week report, but active treatment was uncertain. Personal report Personal report
Symptoms can precede a clear benefit. The blinded participant describes dizziness in week one, bowel changes in week two and burping after week three. Their previous Retatrutide trial felt faster; that comparison establishes neither Amycretin onset nor a need for higher doses after GLP-1 exposure. Personal report

How long the reported feelings last

One specific 1–2-day interval. The Australian participant felt quiet and disconnected on injection day and the next day, lasting 1–2 days. They distinguished it from depression. This is an adverse-feeling interval, not a diagnosis, appetite-benefit window or bodily half-life. Personal report
Appetite wear-off remains unknown. The same person describes reduced appetite and persistent constipation across nine months, without a within-week hunger curve or post-stop offset. Discussed days-to-weeks residual effects are class-based reasoning, not an observed Amycretin stopping timeline. Personal report Community

Courses, stopping and restarting

Months-long courses, not a validated on/off cycle. The participant account spans nine months. Community discussion follows continuous trial treatment and titration/maintenance, rather than a demonstrated 4–8-week cycle. Formal study durations describe the observation period, not a lasting reset of appetite. Personal report Community
The off-drug outcome is unresolved. The former participant moved to Wegovy, then Tirzepatide, after the trial; that transition cannot reveal Amycretin's off-drug effect. Lower-dose restarts and regain expectations in earlier discussions borrow from the wider GLP-1 class; no Amycretin-specific restart or taper schedule was established. Personal report Community

What could change the experience

Digestive effects and low intake. Constipation persisted throughout the positive nine-month report. The blinded account adds fatigue, diarrhoea, slight nausea and burping, with possible other explanations. Community concerns about insufficient food/protein and lean mass matter under strong appetite suppression; weight loss is not proof of muscle preservation. Personal report Personal report Community
Mood and energy deserve their own attention. Less food noise did not bring an energy boost in the expanded account. The recurring disconnected feeling is a separate concern, not simply successful appetite control. Personal report
Comparisons do not validate stacks. Community discussion generally compares Amycretin with other incretins/amylins rather than combining them. It already engages two appetite pathways; extra GLP-1 or amylin drugs add interaction uncertainty. Broader class concerns include gallbladder/pancreatitis issues and hypoglycaemia with insulin or sulfonylureas, rather than proven Amycretin-specific interaction rates. Community
A listing is not an identified trial product. Opened availability threads mostly contain anticipation, not completed self-use logs. A vial name does not establish identity, purity or sterility. No universal storage life follows from a research label. Reddit · r/Retatrutide Community

What the community adds beyond trial headlines

A strong positive account with a persistent tradeoff. The Australian participant would consider returning to Amycretin and describes easier long walks after weight loss. They blamed constipation on inadequate water intake, but that explanation is personal speculation. Personal report Personal report
A slower, uncertain account. The former Retatrutide-trial participant alternated between thinking they had active Amycretin and placebo. Fullness and small later scale changes coexisted with fatigue and digestive complaints. Their uncertainty is not proven drug nonresponse. Personal report
The tolerability debate is unresolved. In the oral-trial investor thread, some commenters emphasise short maintenance exposure and possible later efficacy; another calls injectable tolerability disappointing. These are interpretations of study news, not competing personal outcomes. A pill's convenience does not settle which form someone would tolerate. Reddit · r/NovoNordisk_Stock
One molecule does not settle the ranking. The peptide discussion debates Retatrutide superiority and possible extra GI effects from dual satiety. Those questions concern appetite control, tolerability and individual response; separate trial headlines cannot settle them. Reddit · r/glp1peptides
Body composition and supportive habits remain questions. Community discussion credits protein-focused intake, resistance training, hydration and smaller meals during strong appetite suppression. These are broader habits people discuss, not evidence that Amycretin spares muscle or a prescription for managing its side effects. Community

What the clinical studies measured

Early weight-loss results are encouraging, not comparative proof. A small subcutaneous obesity trial estimated about 22–24% loss at 36 weeks, with frequent GI events and substantial withdrawal. Separate diabetes-population sponsor results were lower. These support further investigation, not a winner ranking or an individual forecast. Official context Official context
Measured SC elimination. Table S9 reports geometric-mean terminal half-lives of 79.0–87.9 hours after single doses and 88.0–99.0 hours with repeated weekly dosing. These human SC measurements are not appetite duration or an oral estimate. Circulated 160–180-hour minipig/patent lore is animal-origin material, not human timing. Official context Community
Formulation and exposure matter. The oral phase 1 trial included 50 mg daily and two 50 mg tablets taken as one daily dose, after titration. Its accessible abstract supplies no numerical oral terminal half-life. Those trial tablets do not establish an injectable dose or a consumer cycle. Official context
A separate mood event. The appendix records an anhedonia-related withdrawal—loss of pleasure—in one participant. This does not diagnose or validate the online account's disconnected feeling. Official context